PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a consolidated revenue of €6.1 million for the first quarter of 2010 versus €2.6 million in Q1 2009.
